Comprehensive criteria for assessing therapy-induced toxicity
- PMID: 2400936
- DOI: 10.3109/07357909009017560
Comprehensive criteria for assessing therapy-induced toxicity
Abstract
Methods of assessing and reporting toxic reactions induced by therapy, particularly chemotherapy, need improvements. Accurate and reliable reporting of therapy-induced toxicity will be necessary for quality clinical research including drug development and for implementation of complex multimodality treatments, currently, however, the extent and quality of reporting of toxic reactions vary widely. Whereas standard and widely accepted criteria have been established for assessing and reporting therapeutic response, no such criteria exist for toxicity. We have developed comprehensive criteria for assessing and reliably reporting toxic reactions. We have reduced the degree of subjectivity in assigning grades by using primarily objective methods. An attempt has been made to standardize the "morbidity impact" of each toxicity grade irrespective of the organ system involved.
Similar articles
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982 Dec;5(6):649-55. Am J Clin Oncol. 1982. PMID: 7165009 No abstract available.
-
A reporting system for the assessment of chemotherapy toxicity.J Oncol Pharm Pract. 2005 Jun;11(2):63-7. doi: 10.1191/1078155205jp154oa. J Oncol Pharm Pract. 2005. PMID: 16460607
-
Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.Support Care Cancer. 2016 Jun;24(6):2411-20. doi: 10.1007/s00520-015-3032-y. Epub 2015 Dec 3. Support Care Cancer. 2016. PMID: 26634561
-
Assessment of quality of life during chemotherapy.Acta Oncol. 2001;40(2-3):175-84. doi: 10.1080/02841860151116222. Acta Oncol. 2001. PMID: 11441930 Review.
-
Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting.Nouv Rev Fr Hematol (1978). 1991;33(3):257-62. Nouv Rev Fr Hematol (1978). 1991. PMID: 1956763 Review.
Cited by
-
Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.BMC Cancer. 2023 Nov 14;23(1):1109. doi: 10.1186/s12885-023-11541-7. BMC Cancer. 2023. PMID: 37964212 Free PMC article.
-
Phase II study of tallysomycin S10b in patients with advanced head and neck cancer.Invest New Drugs. 1990 Aug;8(3):325-8. doi: 10.1007/BF00171848. Invest New Drugs. 1990. PMID: 1703132
-
Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study).Clin Transl Oncol. 2011 Apr;13(4):254-60. doi: 10.1007/s12094-011-0650-9. Clin Transl Oncol. 2011. PMID: 21493186 Clinical Trial.
-
Phase II study of cisplatin, 5-fluorouracil and interferon-alpha in recurrent carcinoma of the cervix.Invest New Drugs. 1995;13(1):73-6. doi: 10.1007/BF02614224. Invest New Drugs. 1995. PMID: 7499112 Clinical Trial.
-
Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.Cancer Chemother Pharmacol. 1996;37(3):254-8. doi: 10.1007/BF00688325. Cancer Chemother Pharmacol. 1996. PMID: 8529286 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources